2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
11
NIH
3
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Interventions
pembrolizumab
1032
Carboplatin
969
Paclitaxel
942
Gemcitabine
799
Cisplatin
755
Docetaxel
698
Bevacizumab
638
Nivolumab
520
Pemetrexed
507
Capecitabine
475
Cyclophosphamide
471
Fluorouracil
425
Dexamethasone
410
Rituximab
391
Oxaliplatin
352
Injections
345
Trastuzumab
313
atezolizumab
311
Cetuximab
291
Leucovorin
289
Irinotecan
271
130-nm albumin-bound paclitaxel
256
Prednisone
251
Ipilimumab
244
Doxorubicin
241
Lenalidomide
231
Fulvestrant
226
fludarabine
217
durvalumab
211
Erlotinib Hydrochloride
196
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Molecular Diagnostic Techniques
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled